ArticleHeart rhythm O22025
Long-term outcomes of atrial antitachycardia pacing to prevent progression to permanent atrial fibrillation in patients implanted with pacemakers.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrogram Transition Patterns During Atrial Antitachycardia Pacing-Mediated Termination.Journal of arrhythmia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A second-generation atrial antitachycardia pacing (ATP), reactive ATP (rATP), was effective in preventing progression to permanent atrial fibrillation (AF) in patients with sick sinus syndrome (SSS) over a 2-year follow-up period. However, its long-term results and efficacy in patients with atrioventricular block (AVB) remain uncertain. Objective: This study aimed to evaluate the long-term efficacy of rATP in patients implanted with pacemakers owing to SSS and AVB. Methods: The incidence of progression to permanent AF was compared between 2 groups of the 349 patients implanted with dual-chamber pacemakers (134 with rATP function [rATP group] and 215 without rATP [control group]). Results: During the follow-up period (1906 ± 950 days), 57.5% of the patients in the rATP group and 55.3% in the control group experienced atrial tachyarrhythmia episodes lasting > 1 minute ( Conclusion: Progression to permanent AF was reduced by rATP in patients with SSS and AVB. Treatment efficacy and safety were sustained over 5 years. Clinical benefits and the risk of battery drainage should be balanced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.